Lamotrigine hydrate  (Synonyms: LTG hydrate; BW430C hydrate)

Lamotrigine hydrate is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine hydrate selectively blocks voltage-gated Na⁺ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine hydrate can be used for the research of epilepsy, focal seizure, et al^[1][2].

Lamotrigine hydrate inhibits Veratrine evoked release of glutamate and aspartate with ED₅₀ values of 21 μM for both amino acids, but Lamotrigine hydrate is less potent in the inhibition of GABA release (ED₅₀=44 μM. At concentrations up to 300 μM, LTG has no effect on patassium-evoked amino acid^[1].
Lamotrigine hydrate is some five times less potent in the inhibition of Veratrine-evoked [³H]acetylcholine release (ED₅₀=100 μM) than in glutamate or aspartate release^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Lamotrigine hydrate (IP, 30 min before pentylenetetrazol; 10 mg/kg, 15 mg/kg or 20 mg/kg) decreases the seizure intensity at the higher doses, it increases the latency to the first pentylenetetrazol-induced seizure in all studied doses compared with the controls^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

274.11

C₉H₉Cl₂N₅O

375347-20-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. M J Leach, et al. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia. Sep-Oct 1986;27(5):490-7.  [Content Brief]

  [2]. Damianka P Getova, et al. A study of the effects of lamotrigine on mice using two convulsive tests. Folia Med (Plovdiv). Apr-Jun 2011;53(2):57-62.  [Content Brief]